EMA Authorised: Topotecan Hospira (topotecan) — Pfizer Europe MA EEIG

View source ↗

Summary

EMA authorised Topotecan Hospira for use in small cell lung cancer and uterine cervical neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer
• Uterine Cervical Neoplasms

Drugs mentioned

• Topotecan Hospira (topotecan)

Snippet

Status: Authorised. Therapeutic area: Uterine Cervical Neoplasms;Small Cell Lung Carcinoma. MAH: Pfizer Europe MA EEIG. Decision date: 31/03/2026